Mpox vaccine (2024)
Estimated value
—
Awarded value
£1
Suppliers
1
Lots
1
Published
10 Oct 2024
Description
A contract for a vaccine indicated for primary vaccination against smallpox, Mpox and disease caused by vaccinia virus in adults. Delivery of more than 150,000 doses will be required over the initial term, with an option to extend for up to an additional 24 months. Value - The value has been withheld so as not to prejudice the legitimate commercial interest of the supplier.
Scope
- Reference
- CF-2619800D0O000000rwimUAA
- Commercial tool
- Standalone contract
- Contract dates
- 11 Sept 2024 to 31 Dec 2027
- CPV classifications
- 33651600
Submission & procedure
- Submission deadline
- 11 Sept 2024, 12:00 pm
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£1
Award date
11 Sept 2024
Contract start
11 Sept 2024
Contract end
31 Dec 2027
Awarded suppliers· 1 supplier
Awarded 11 Sept 2024 · Contract period 11 Sept 2024 — 31 Dec 2027
Other contracts from UK HEALTH AND SECURITY AGENCY
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to Bavarian Nordic A/S· 7
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| Rabies Vaccine Response | contract | — | 05 Sept 2025 |
| Rabies Vaccine Response | contract | — | 29 Aug 2025 |
| Rabies Vaccine Response | contract | — | 29 Aug 2025 |
| Mpox vaccine (2024) | contract | — | 10 Oct 2024 |
| Jynneos suspension for Injection vaccine. | contract | £1 | 14 Sept 2022 |
| Jynneos Vaccine - | contract | — | 22 Aug 2022 |
| PHE_Urgent requirement for Imvanex vaccine | contract | £20k | 25 Oct 2021 |